Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

(2018) K. Cusi et al.   DIABETIC MEDICINE

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study

(2018) Niina Matikainen et al.   DIABETES OBESITY & METABOLISM

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

(2017) Tisha R Joy et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

(2017) Wenhuan Feng et al.   Journal of Diabetes

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

(2016) K. Cusi et al.   DIABETES OBESITY & METABOLISM

Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide

(2016) Savvoula Savvidou et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

(2016) Mark M. Smits et al.   DIABETOLOGIA

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) et al.   DIABETOLOGIA

Nonalcoholic Fatty Liver Disease

(2016) Fernando Bril et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin

(2016) Anna Vanderheiden et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus

(2016) Changyu Pan et al.   Drugs in research & development

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

(2015) Annayya R. Aroor et al.   DIABETES

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

(2015) An Tang et al.   DIABETES CARE

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes

(2015) Hiroyuki Kato et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury

(2015) Masahiro Asakawa et al.   SpringerPlus

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)

(2014) Yuichiro Eguchi et al.   HEPATOLOGY RESEARCH

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

(2012) Takamasa Ohki et al.   TheScientificWorldJOURNAL

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

(2011) A. E. Pontiroli et al.   DIABETES OBESITY & METABOLISM

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

(2011) S. L. Samson et al.   DIABETOLOGIA

Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus

(2011) Tomoyuki Iwasaki et al.   HEPATO-GASTROENTEROLOGY